Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

NCT00084630 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

NIH

Sponsor class

Conditions

Adult Fibrosarcoma
Dermatofibrosarcoma Protuberans
Recurrent Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)